Patent Application
20240217992
The present application claims the right of the priority of Chinese patent application 202110459864X filed on Apr. 27, 2021. The contents of the above Chinese patent application are incorporated herein by reference in its entirety.
The present disclosure relates to a retinoic acid receptor agonist, a preparation method therefor, an intermediate thereof, a pharmaceutical composition thereof, and a use thereof.
Retinoic acid is a class of vitamin A metabolites that initiates and regulates gene expression through activation of nuclear receptors, which is a key regulator of cell growth, differentiation, proliferation, and programmed apoptosis, and is involved in physiopathological processes, such as embryonic development, tissue differentiation, and tumors. The physiological effects of retinoic acid are mediated by two types of receptors, the retinoic acid receptor (RAR) and the retinoid X receptor (RXR). Among them, the retinoic acid receptor (RAR) belongs to the nuclear receptor superfamily, including α, β, and γ. RARβ is subdivided into β1, β2, β3, β4, etc. The signaling of retinoic acid receptor ultimately functions through gene transcriptional regulation, and a complete signaling pathway of retinoic acid consists of the ligand retinoic acid, receptor dimerization, the retinoic acid response element (RARE), and coregulators.
The distribution of retinoic acid receptor (RAR) is temporally and spatially specific during cell development, and different retinoic acid receptor pathways have different functions for cell development. In general, RARα is most widely expressed in cells and is present in most tissues; RARβ is highly expressed in the central nervous system; and RARγ is only expressed in skin, epithelial, and cartilage tissues. In humans and adult rats, expression products of RARγ are highly restricted to the skin, with low expression in other organs. Studies have shown that RARγ selective agonists have efficacy in the treatment of conditions, such as facial acne and psoriasis.
For example, Trifarotene (trade name: Aklief) is a RARγ selective agonist developed by Galderma Research and Development, which was approved by the US FDA in 2019 for the treatment of facial acne in adolescents aged 9 years and older (Lesley J. Scott, Drugs 2019, 79, 1905-1909). Thoreau et al. reported in the literature (Bioorganic & Medicinal Chemistry Letters 2018, 28, 1736-1741) that compound 10d is also a RARγ selective agonist:
The present disclosure is to provide a retinoic acid receptor agonist, a preparation method therefor, an intermediate thereof, a pharmaceutical composition thereof, and a use thereof.
On the one hand, the present disclosure provides a compound of formula (I):
form
In some embodiments, in the definition of R1, R2, and R3, each C1-6 alkyl may be independently C1-4 alkyl, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or tert-butyl, for another example, methyl.
In some embodiments, in the definition of R1, R2, and R3, when any two of R1, R2, and R3, together with the Si atom to which they are attached, form a 4- to 12-membered heterocycloalkyl ring, each 4- to 12-membered heterocycloalkyl ring may be independently a 5- to 10-membered heterocycloalkyl ring, for example, a 5- to 6-membered heterocycloalkyl ring. Each 4- to 12-membered heterocycloalkyl ring may comprise independently 2 Si atoms and 0, 1, or 2 heteroatoms independently selected from N, O, and S, for example, 2 Si atoms.
In some embodiments, in the definition of R4, each C1-6 alkyl is independently C1-4 alkyl, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or tert-butyl.
In some embodiments, in the definition of R4a and R4b, each C1-6 alkyl may be independently C1-4 alkyl, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or tert-butyl, for another example, ethyl.
In some embodiments, in the definition of R4a and R4b, when R4a and R4b, together with the N atom to which they are attached, form a 4- to 6-membered heterocycloalkyl ring, the 4- to 6-membered heterocycloalkyl ring may be a 5-membered heterocycloalkyl ring; the 4- to 6-membered heterocycloalkyl ring may comprise 1 N atom. The 4- to 6-membered heterocycloalkyl ring may be
In some embodiments, in the definition of R4, the —NR4aR4b may be
In some embodiments, in the definition of R4c, R4d, and R4e, each C1-6 alkyl may be independently C1-4 alkyl, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or tert-butyl.
In some embodiments, in the definition of R4f, R4g, and R4h, each C1-6 alkyl may be independently C1-4 alkyl, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or tert-butyl, for another example, methyl.
In some embodiments, in the definition of ring A, ring B, and ring C, each 4- to 12-membered heterocyclic ring may be independently a 5- to 10-membered heterocyclic ring, for example, a 5- to 6-membered heterocyclic ring, for another example, a 6-membered heterocyclic ring. Each 4- to 12-membered heterocyclic ring may comprise independently 2 Si atoms and 0, 1, or 2 heteroatoms independently selected from N, O, and S, for example, 2 Si atoms. The 4- to 12-membered heterocyclic ring may be a 6-membered heterocyclic ring with 2 Si atoms.
In some embodiments, in the definition of R5, the C1-6 alkoxy may be C1-4 alkoxy, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, or tert-butoxy, for another example, ethoxy, n-propoxy, or n-butoxy.
In some embodiments, in the definition of R5a, the halogen may be fluorine, chlorine, bromine, or iodine.
In some embodiments, in the definition of R5, the C1-6 alkoxy substituted by one or more than one R5a may be C1-6 alkoxy substituted by one R5a, for example, C1-6 alkoxy substituted by one hydroxyl group, for another example, —OCH2CH2OH, —OCH2CH2CH2OH, or —OCH2CH2CH2CH2OH.
In some embodiments, in the definition of R6, the C1-6 alkyl may be C1-4 alkyl, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or tert-butyl.
In some embodiments, R1, R2, and R3 may be each independently C1-6 alkyl, for example, methyl.
In some embodiments, any two or all of R1, R2, and R3 may be each independently C1-6 alkyl, for example, methyl;
In some embodiments, R4 may be —NR4aR4b, for example,
In some embodiments, R4a may be ethyl.
In some embodiments, R4b may be ethyl.
In some embodiments, R4a and R4b may be ethyl.
In some embodiments, each R4f may be independently methyl.
In some embodiments, each R4g may be independently methyl.
In some embodiments, each R4h may be independently methyl.
In some embodiments, m may be 2.
In some embodiments, n may be 2.
In some embodiments, q may be 2.
In some embodiments,
may be
for example,
In some embodiments,
may be
for example,
In some embodiments,
may be
for example,
In some embodiments, R5 may be C1-6 alkoxy substituted by one or more than one R5a, for example, C1-6 alkoxy substituted by one R5a, for another example, —OCH2CH2OH, —OCH2CH2CH2OH, or —OCH2CH2CH2CH2OH.
In some embodiments, R5a may be hydroxyl.
In some embodiments, R6 may be H.
In some embodiments, R5a is hydroxyl, and R6 is H.
In some embodiments, R1, R2, and R3 are each independently C1-6 alkyl;
In some embodiments, two of R1, R2, and R3 are each independently C1-6 alkyl;
In some embodiments, the compound of formula (I) has a structure of formula (I-a):
In some embodiments, the compound of formula (I) has a structure of formula (I-b):
In some embodiments, the compound of formula (I) has a structure of formula (I-c):
In some embodiments, the compound of formula (I) has a structure of formula (I-d):
In some embodiments, the compound of formula (I) has a structure of formula (I-b-1):
In some embodiments, the compound of formula (I) has a structure of formula (I-c-1):
In some embodiments, the compound of formula (I) has a structure of formula (I-d-1):
In some embodiments, the compound of formula (I) may be:
On the other hand, the present disclosure also provides a preparation method for the compound of formula (I), which is any one of the following methods:
is a group in which
is protected by a carboxyl protecting group (for example,
is a group in which
is protected by a carboxyl protecting group (for example,
In the preparation method for the compound of formula (I), the reaction conditions and reagents of method (A), method (B), or method (C) may be the conventional conditions and reagents of this type of reaction in the art, and the following conditions and reagents are preferred for the present disclosure.
In some embodiments, the solvent in the method (A), method (B), or method (C) may be an ether solvent, for example, tetrahydrofuran. The base may be an inorganic base (for example, sodium hydroxide); the base can be used in the form of an aqueous solution, and the concentration of the aqueous solution of the base may be 1 M to 2 M. The temperature of the reaction may be 20° C. to 50° C., for example, 40° C.
In some embodiments, the process of the reaction in the method (A), method (B), or method (C) can be monitored using conventional test methods in the art (for example, TLC, GC, HPLC, or NMR), and those skilled in the art can determine when to terminate the reaction based on the results of the monitoring (including the degree of conversion of raw materials, the generation of impurities, etc.) to obtain a better result of the reaction, and the reaction time of the reaction may be 2 hours.
In some embodiments, the preparation method for the compound of formula (II-a) comprises the following steps: in a solvent, performing a coupling reaction as shown below between a compound of formula (III-a) and a compound of formula (IV) (e.g., the condition can be in the presence of a base and a catalyst) to obtain the compound of formula (II-a);
and other groups are as defined above.
In some embodiments, the preparation method for the compound of formula (I) may further comprise a preparation method for the compound of formula (II-a), (II-b), or (II-c).
In the preparation method for the compound of formula (II-a), (II-b), or (II-c), the reaction conditions and reagents of the coupling reaction may be conventional conditions and reagents of this type of reaction in the art, and the following conditions and reagents are preferred for the present disclosure.
In some embodiments, in the preparation method for the compound of formula (II-a), (II-b), or (II-c), the solvent may be a mixed solvent of an ether solvent (for example, dioxane) and water; in the mixed solvent, the volume ratio of the ether solvent and water may be 4:1. The base may be an inorganic base (for example, sodium bicarbonate). The catalyst is a palladium catalyst (for example, Pd(dppf)Cl2). The temperature of the coupling reaction may be 90° C. to 130° C., for example, 120° C. The coupling reaction can be carried out under microwave irradiation and/or in an inert (for example, nitrogen) atmosphere.
In some embodiments, in the preparation method for the compound of formula (II-a), (II-b), or (II-c), the process of the coupling reaction can be monitored using conventional test methods in the art (for example, TLC, GC, HPLC, or NMR), and those skilled in the art can determine when to terminate the reaction based on the results of the monitoring (including the degree of conversion of raw materials, the generation of impurities, etc.) to obtain a better result of the reaction, and the reaction time of the reaction may be 1 hour.
In some embodiments, a preparation method for the compound of formula (IV):
the preparation method comprises the following steps: in a solvent, performing a coupling reaction as shown below between a compound of formula (V) and bis(pinacolato)diboron (e.g., the condition can be in the presence of a base and a catalyst) to obtain the compound of formula (IV);
Among them, each group is as defined above.
In some embodiments, the preparation method for the compound of formula (I), (II-a), (II-b), or (II-c) may further comprise a preparation method of the compound of formula (IV).
In the preparation method of the compound of formula (IV), the reaction conditions and reagents of the reaction may be conventional conditions and reagents of this type of reaction in the art, and the following conditions and reagents are preferred for the present disclosure.
In some embodiments, in the preparation method of the compound of formula (IV), the solvent of the coupling reaction may be an ether solvent (for example, dioxane). The base of the coupling reaction may be an inorganic base (for example, potassium acetate). The catalyst of the coupling reaction is a palladium catalyst (for example, Pd(dppf)Cl2). The temperature of the coupling reaction may be 90° C. to 130° C., for example, 120° C. The coupling reaction can be carried out under microwave irradiation and/or in an inert (for example, nitrogen) atmosphere. The solvent of the cyclization reaction may be acetonitrile (anhydrous acetonitrile). The temperature of the cyclization reaction may be 20° C. to 60° C., for example, 50° C. The cyclization reaction can be carried out in an inert (for example, argon) atmosphere.
In some embodiments, in the preparation method for the compound of formula (IV), the process of the reaction can be monitored using conventional test methods in the art (for example, TLC, GC, HPLC, or NMR), and those skilled in the art can determine when to terminate the reaction based on the results of the monitoring (including the degree of conversion of raw materials, the generation of impurities, etc.) to obtain a better result of the reaction. The reaction time of the coupling reaction may be 1 hour. The reaction time of the cyclization reaction may be 1 hour.
On the other hand, the present disclosure also provides a compound of formula (V), (IV), (II-a), (II-b), or (II-c):
In some embodiments, the compound of formula (V) may be:
In some embodiments, the compound of formula (IV) may be:
In some embodiments, the compound of formula (II-a) may be:
On the other hand, the present disclosure also provides a pharmaceutical composition, comprising (i) the compound of formula (I), the tautomer thereof, the stereoisomer thereof, the isotope derivative thereof, or the pharmaceutically acceptable salt thereof, and (ii) a pharmaceutically acceptable carrier.
On the other hand, the present disclosure also provides a use of the compound of formula (I), the tautomer thereof, the stereoisomer thereof, the isotope derivative thereof, or the pharmaceutically acceptable salt thereof as a medicament.
On the other hand, the present disclosure also provides a use of the compound of formula (I), the tautomer thereof, the stereoisomer thereof, the isotope derivative thereof, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition as a retinoic acid receptor (e.g., retinoic acid receptor γ) agonist.
The present disclosure also provides a use of the compound of formula (I), the tautomer thereof, the stereoisomer thereof, the isotope derivative thereof, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition in the manufacture of a medicament for the treatment or prevention of a disease associated with retinoic acid receptor (e.g., retinoic acid receptor γ).
In the present disclosure, the disease associated with retinoic acid receptor (e.g., retinoic acid receptor γ) may be acne (including common acne, rosacea, nodulocystic acne, acne conglobata, and secondary acne caused by sun exposure or medication therapy), pimples, psoriasis, ichthyosis, keratosis, hyperpigmentation, dry eye syndrome, etc.
On the other hand, the present disclosure also provides a method for the treatment of a disease associated with retinoic acid receptor (e.g., retinoic acid receptor γ), comprising administering to a subject in need of the treatment the compound of formula (I) (preferably, administering to a subject in need of the treatment a therapeutically effective amount of the compound of formula (I)), the tautomer thereof, the stereoisomer thereof, the isotope derivative thereof, or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition.
The positive and progressive effect of the present disclosure is to provide a retinoic acid receptor agonist, a preparation method therefor, an intermediate thereof, a pharmaceutical composition thereof, and a use thereof. The compound has relatively high agonist activity for retinoic acid receptor γ and selectivity to retinoic acid receptor γ, and has relatively low hepatocyte stability. It is shown that the compound has better activity in local skin, and is metabolized faster in hepatocytes after entering the systemic circulation. It is indicated that the drug is safer and excellent in druggability, and can potentially be used for treating diseases associated with retinoic acid receptor (e.g., retinoic acid receptor γ).
Unless otherwise specified, the terms used in the present disclosure have the following definitions, and the definitions of terms not involved below are as commonly understood by those skilled in the art.
The term “tautomer” refers to a functional group isomer resulting from the rapid movement of an atom in a molecule between two positions. For example, acetone and 1-propen-2-ol can be transformed into each other by rapid movement of a hydrogen atom on the oxygen and α-carbon.
The term “stereoisomer” refers to isomers in which the atoms or groups of atoms in the molecule are connected in the same order but with different spatial arrangements, for example, cis-trans isomers (for example, Z-isomers, E-isomers), optical isomers (for example, enantiomers, diastereomers), atropisomers, etc. These stereoisomers can be separated, purified, and enriched by asymmetric synthesis methods or chiral separation methods (including, but not limited to, thin-layer chromatography, rotary chromatography, column chromatography, gas chromatography, high-pressure liquid chromatography), or these stereoisomers can be obtained by chiral resolution through bonding (for example, chemical bonding) or salt formation (for example, physical bonding) with other chiral compounds. Optical isomers include enantiomers and diastereomers. All these isomers and their mixtures are included within the scope of the present disclosure.
The term “isotope derivative” refers to a compound in which one or more than one atom is substituted by one or more than one atom with a specific atomic mass or mass number. Examples of isotopes that can be incorporated into a compound include, but are not limited to, isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, sulfur, and chlorine (for example, 2H, 3H, 13C, 14C, 15N, 18O, 17O, 18F, 35S, and 36Cl). Isotope compounds can typically be prepared by replacing non-isotope-labeled reagents with isotope-labeled reagents according to the methods described herein. Typical examples of isotope derivatives include a deuterated compound.
The term “pharmaceutically acceptable salt” refers to a salt prepared by a compound with a relatively non-toxic, pharmaceutically acceptable acid or base. When the compound contains a relatively acidic functional group, a base addition salt can be obtained by bringing the neutral form of the compound into contact with a sufficient amount of a pharmaceutically acceptable base in a pure solution or a suitable inert solvent. When the compound of the present disclosure contains a relatively basic functional group, an acid addition salt can be obtained by bringing the neutral form of the compound into contact with a sufficient amount of a pharmaceutically acceptable acid in a pure solution or a suitable inert solvent. When the compound contains a relatively acidic functional group and a relatively basic functional group, it can be converted into a base addition salt or an acid addition salt.
The term “halogen” means fluorine, chlorine, bromine, or iodine.
The term “hydroxyl” means an —OH group.
The term “alkyl” refers to a saturated linear or branched monovalent hydrocarbon group with a certain number of carbon atoms. C1-6 alkyl refers to an alkyl group with 1 to 6 (for example, 1, 2, 3, 4, 5, or 6) carbon atoms, including C1 alkyl, C2 alkyl, C3 alkyl, C4 alkyl, C5 alkyl, and C6 alkyl, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, etc.
The term “alkoxy” refers to the group —O—RX, wherein RX is alkyl as defined above.
The term “x- to y-membered” in the cyclic group described herein means that the number of atoms in the ring is x to y. For example, cyclopropyl is 3-membered, tetrahydropyrrolyl is 5-membered, and piperidinyl is 6-membered.
The term “substituted” or “substituent” means that one or more than one hydrogen atom is replaced by a specified group. When the substitution position is not specified, the substitution can be at any position, but is only allowed if it forms a stable or chemically available chemical.
The term “protecting group” includes, but is not limited to, “hydroxyl protecting group” or “carboxyl protecting group”, and refers to a protecting group suitable for preventing side reactions of the group. The term “hydroxyl protecting group” refers to a protecting group suitable for preventing the side reaction on hydroxyl. Representative hydroxyl protecting groups include, but are not limited to: alkyl, for example, methyl, ethyl, and tert-butyl; acyl, for example, alkanoyl (e.g., acetyl); arylmethyl, for example, benzyl (Bn), p-methoxybenzyl (PMB), 9-fluorenylmethyl (Fm), and diphenylmethyl (benzhydryl, DPM); silyl, for example, trimethylsilyl (TMS) and tert-butyl dimethylsilyl (TBS).
The term “treatment” refers to therapeutic therapy. When referring to a specific condition, treatment refers to: (1) alleviating the disease or one or more than one biological manifestation of the condition, (2) interfering with (a) one or more than one point in the biological cascade that leads to or causes the condition or (b) one or more than one biological manifestation of the condition, (3) ameliorating one or more than one symptom, effect, or side effect associated with the condition, or one or more than one symptom, effect, or side effect associated with the condition or the treatment thereof, or (4) slowing the progression of the condition or one or more than one biological manifestation of the condition.
The term “therapeutically effective amount” refers to the amount of a compound that is sufficient to effectively treat or prevent the disease or condition described herein when administered to a patient. The “therapeutically effective amount” will vary depending on the compound, the condition and its severity, and the age of the patient to be treated, but it can be adjusted as necessary by those skilled in the art. Doses beyond this range can also be used depending on the dosage form and the severity of the disease.
The pharmaceutical composition can be formulated into various types of unit dosage forms according to the therapeutic purpose.
The compounds of the present disclosure can be administered clinically in a conventional manner.
The term “subject” refers to any animal, preferably a mammal, and most preferably a human, that is to be or has been administered a compound or composition. The term “mammal” includes any mammal. Examples of mammals include, but are not limited to, cattle, horses, sheep, pigs, cats, dogs, mice, rats, rabbits, guinea pigs, monkeys, humans, etc., most preferably humans.
The following abbreviations are used herein: K2CO3 represents potassium carbonate; CH3CN or MeCN represents acetonitrile; n-BuLi represents n-butyllithium; TMSCl represents chlorotrimethylsilane; TMS represents trimethylsilyl; B2Pin2 represents bis(pinacolato)diboron; KOAc represents potassium acetate; Pd(dppf)Cl2 represents [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II); MW represents microwave; NBS represents N-bromosuccinimide; DCM represents dichloromethane; NaH represents sodium hydride; DMF represents N,N-dimethylformamide; NaHCO3 represents sodium bicarbonate; KI represents potassium iodide; NaOH represents sodium hydroxide; PE represents petroleum ether; EA represents ethyl acetate; THF represents tetrahydrofuran; TLC represents thin-layer chromatography; HPLC represents high-pressure liquid chromatography; LCMS represents liquid chromatography mass spectrometry.
All patents and publications referred to herein are incorporated herein by reference in their entirety.
On the basis of common knowledge in the art, the above-mentioned preferred conditions can be combined arbitrarily to obtain preferred examples of the present disclosure.
The reagents and raw materials used in the present disclosure are all commercially available or can be prepared according to existing methods.
The present disclosure is further illustrated below by means of examples, but the present disclosure is not limited to the scope of the examples. The experimental methods that haven't illustrated specific conditions in the following examples are selected according to conventional methods and conditions, or according to the product instructions.
4-Bromo-2-iodoaniline (compound 1-1, 5 g, 16.8 mmol) was dissolved in acetonitrile (50 mL) in a 100 mL single-necked flask, and dibromobutane (7.2 g, 33.6 mmol) and potassium carbonate (7 g, 50.4 mmol) were sequentially added thereto at room temperature. After the addition was complete, the mixture was heated to 80° C. in an oil bath and stirred overnight. The solid insoluble material was filtered, then the filtrate was evaporated to dryness by rotary evaporation, and the residue was purified by silica gel column chromatography (mobile phase: petroleum ether) to obtain compound 1-2 (2.6 g, 7.3 mmol) as a yellow oil with a yield of 43.5%.
LCMS [M+1]+=351.9, 353.9.
1-(4-Bromo-2-iodophenyl)pyrrolidine (compound 1-2, 2.6 g, 7.3 mmol) was added into a 100 mL three-necked flask and dissolved in tetrahydrofuran (30 mL), and the mixture was stirred for 5 minutes in a dry ice acetone bath (−78° C.). A mixture of n-butyllithium (0.5 mL, 2.5 M) in tetrahydrofuran was added slowly dropwise to the solution under nitrogen atmosphere, and after the dropwise addition was complete, the reaction mixture was continuously stirred and reacted for 1 hour at −78° C. Then, chlorotrimethylsilane (1.6 g, 14.7 mmol) was added slowly dropwise to the reaction mixture, and the temperature was kept constant at −78° C. After the dropwise addition was complete, the reaction mixture was slowly warmed to room temperature while stirring and stirred overnight. The reaction was quenched by saturated ammonium chloride aqueous solution (10 mL), and the reaction mixture was extracted with ether (3×20 mL). The organic phases were combined, washed with saturated brine (1×10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated to dryness by rotary evaporation to obtain a light yellow residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether=1:20) to obtain compound 1-3 (1.2 g, 4.0 mmol) as a light yellow oil with a yield of 54.5%.
LCMS [M+1]+=298.0, 300.0.
1H NMR (CDCl3, 300 MHz) δ 7.55 (d, J=3 Hz, 1H), 7.45 (dd, J=9 Hz, 3 Hz, 1H), 7.55 (d, J=9 Hz, 1H), 3.02-2.96 (m, 4H), 1.98-1.88 (m, 4H), 0.30 (s, 1H).
1-(4-Bromo-2-(trimethylsilyl)phenyl)pyrrolidine (compound 1-3, 210 mg, 0.7 mmol), bis(pinacolato)diboron (200 mg, 0.8 mmol), potassium acetate (186 mg, 2.0 mmol), and Pd(dppf)Cl2 (16 mg, 0.02 mmol) were added into a 10 mL microwave tube. And dioxane (4 mL) was added into the tube. The microwave tube was sealed under nitrogen atmosphere, then heated, and reacted at 120° C. for 1 hour. After the reaction was complete, the reaction mixture was diluted with petroleum ether (9 mL), separated by flash column chromatography with a small amount of silica gel layer, and filtered to remove inorganic salts and palladium black. The filtrate was concentrated to obtain compound 1-4 (242 mg) as a light brown crude product. The crude product was used directly in the next reaction step without purification.
LCMS [M+1]+=346.2.
1H NMR (DMSO-d6, 800 MHz) δ 7.72 (d, J=1.5 Hz, 1 H), 7.58 (dd, J=1.6, 8.1 Hz, 1 H), 7.04 (d, J=8.1 Hz, 1 H), 3.03 (t, J=6.4 Hz, 4 H), 1.86 (td, J=3.2, 6.4 Hz, 4 H), 1.26 (s, 12 H), 0.24 (s, 9 H).
Ethyl 4′-hydroxy-[1,1′-biphenyl]-4-carboxylate (compound 1-5, 1 g, 4.1 mmol) was dissolved in DCM (15 mL) in a 50 mL single-necked flask. NBS (728 mg, 4.1 mmol) was added thereto in five batches at 25° C., and after the addition was complete, the reaction mixture was stirred for another 1 hour at room temperature. After the stirring was complete, the reaction mixture was concentrated, and the crude product was purified by column chromatography (petroleum ether:ethyl acetate=10:1 to 1:1) to obtain compound 1-6 (1.1 g) as a white solid with a yield of 83.5%.
LCMS [M+1]+=321.0, 323.0.
Ethyl 3′-bromo-4′-hydroxy-[1,1′-biphenyl]-4-carboxylate (compound 1-6, 1.1 g, 3.4 mmol) was placed in a 50 mL single-necked flask and dissolved in DMF (10 mL). NaH (163 mg, 60%, 1.2 eq) was added thereto slowly in an ice water bath at 0° C. The reaction mixture was stirred and reacted for 0.5 hours, and then added dropwise with 2-bromoethyl acetate (678 mg, 4.1 mmol). After the dropwise addition was complete, the reaction mixture was stirred overnight. The system was then added with 30 mL of water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by silica gel column chromatography (petroleum ether:ethyl acetate=100:1 to 1:1) to obtain compound 1-7 (1.0 g) as a white solid with a yield of 72.2%.
1H NMR (DMSO-d6, 800 MHz) δ 8.02-8.00 (m, 2 H), 7.98 (d, J=2.3 Hz, 1 H), 7.84-7.81 (m, J=8.4 Hz, 2 H), 7.75 (dd, J=2.3, 8.6 Hz, 1 H), 7.27 (d, J=8.7 Hz, 1 H), 4.42-4.38 (m, 2 H), 4.36-4.31 (m, 4 H), 2.06 (s, 3 H), 1.34 (t, J=7.2 Hz, 3 H).
Compound 1-4 (242 mg, 0.7 mmol), compound 1-7 (284 mg, 0.7 mmol), sodium bicarbonate (168 mg, 2.0 mmol), and Pd(dppf)Cl2 (16 mg, 0.02 mmol) were added into a 10 mL microwave tube. The system was added with dioxane (4 mL) and H2O (1 mL). The microwave tube was sealed under nitrogen atmosphere, and the reaction mixture was reacted at 120° C. for 1 hour under microwave irradiation. After the reaction was complete, the reaction mixture was diluted with petroleum ether (9 mL) and ethyl acetate (2 mL). The reaction mixture was then dried over anhydrous sodium sulfate, and filtered by a small amount of silica gel layer to remove inorganic salts and palladium black. The filtrate was concentrated to obtain compound 1-8 (382 mg) as a light brown crude product, which was used directly in the next step without further purification.
LCMS [M+1]+=546.2.
Ethyl 4′-(2-acetoxyethoxy)-4′-(pyrrolidin-1-yl)-3′-(trimethylsilyl)-[1,1′:3′,1′-terphenyl]-4-carboxylate (compound 1-8, 382 mg, 0.7 mmol) was placed in a 25 mL single-necked flask. Compound 1-8 was dissolved in tetrahydrofuran (3 mL). NaOH aqueous solution (2 M, 1 mL) was added to the reaction system. The reaction system was stirred for 2 hours at 40° C. After the reaction was complete, the reaction system was slowly adjusted to neutrality with formic acid. The reaction mixture was directly purified by reversed-phase column chromatography (H2O/MeCN, 30% to 100%, 0.05% FA), and the resulting eluate was concentrated until a large amount of solid precipitated, filtered, washed with acetonitrile (1 mL×2), and dried to obtain compound I-1 (87 mg) as a white solid product with a yield of 26.2%.
LCMS [M+1]+=476.2.
1H NMR (DMSO-d6, 800 MHz) δ 7.98-7.96 (m, 2 H), 7.81-7.79 (m, 2 H), 7.66-7.64 (m, 2 H), 7.61-7.58 (m, 2 H), 7.28 (d, J=8.3 Hz, 1 H), 7.22 (d, J=8.7 Hz, 1 H), 4.09 (t, J=5.2 Hz, 2 H), 3.72-3.69 (m, 2 H), 2.99 (t, J=5.4 Hz, 4 H), 1.88 (td, J=3.1, 6.3 Hz, 4 H), 0.28-0.26 (m, 9 H).
The reaction flask was added with ethyl 3′-bromo-4′-hydroxy-[1,1′-biphenyl]-4-carboxylate (compound 1-6, 110 mg, 0.34 mmol), acetonitrile (4 mL), 3-chloropropyl acetate (136 mg, 1 mmol), potassium carbonate (138 mg, 1 mmol), and a catalytic amount of potassium iodide, and then the reaction mixture was stirred for 12 hours at 80° C. The reaction mixture was filtered, concentrated, and purified by silica gel column chromatography (petroleum ether:ethyl acetate=100:1 to 1:1) to obtain compound 2-2 (112 mg) as a white solid with a yield of 78.2%.
LCMS [M+1]+=421.0, 423.0.
Compound 1-4 (60 mg, 0.17 mmol), compound 2-2 (71.4 mg, 0.17 mmol), sodium bicarbonate (42 mg, 0.5 mmol), and Pd(dppf)Cl2 (8 mg, 0.01 mmol) were added into a 10 mL microwave tube. The system was added with dioxane (4 mL) and H2O (1 mL). The microwave tube was sealed under nitrogen atmosphere, and the reaction mixture was reacted at 120° C. for 1 hour under microwave irradiation. After the reaction was complete, the reaction mixture was diluted with petroleum ether (9 mL) and ethyl acetate (2 mL). The reaction mixture was then dried over anhydrous sodium sulfate, and filtered by a small amount of silica gel layer to remove inorganic salts and palladium black. The filtrate was concentrated to obtain compound 2-3 (90 mg) as light brown crude product, which was used directly in the next step without further purification.
LCMS [M+1]+=560.2.
Ethyl 4′-(3-acetoxypropoxy)-4″-(pyrrolidin-1-yl)-3″-(trimethylmethylsilyl)-[1,1′:3′,1″-terphenyl]-4-carboxylate (compound 2-3, 90 mg of the crude product) was placed in a 25 mL single-necked flask. Compound 2-3 was dissolved in tetrahydrofuran (3 mL). NaOH aqueous solution (1 M, 1 mL) was added to the reaction system. The reaction system was stirred for 2 hours at 40° C. After the reaction was complete, the reaction system was slowly adjusted to neutrality with formic acid. The reaction mixture was directly purified by reversed-phase column chromatography (H2O/MeCN, 30% to 100%, 0.05% FA), and the resulting eluate was concentrated until a large amount of solid precipitated, filtered, washed with acetonitrile (1 mL×2), and dried to obtain compound I-2 (19 mg) as a white solid product.
LCMS [M+1]+=490.2.
1H NMR (800 MHz, DMSO-d6) δ 8.00-7.96 (m, J=8.5 Hz, 2 H), 7.83-7.80 (m, J=8.5 Hz, 2 H), 7.68 (dd, J=2.4, 8.5 Hz, 1 H), 7.62 (dd, J=2.3, 9.7 Hz, 2 H), 7.55 (dd, J=2.2, 8.3 Hz, 1 H), 7.30 (d, J=8.3 Hz, 1 H), 7.21 (d, J=8.7 Hz, 1 H), 4.12 (t, J=6.3 Hz, 2 H), 3.53 (t, J=6.2 Hz, 2 H), 3.01 (br. s., 4 H), 1.89 (br. s., 4 H), 1.85 (t, J=6.3 Hz, 2 H), 0.28 (s, 9 H).
The reaction flask was added with ethyl 3′-bromo-4′-hydroxy-[1,1′-biphenyl]-4-carboxylate (compound 1-6, 110 mg, 0.34 mmol), acetonitrile (4 mL), 4-chlorobutyl acetate (150 mg, 1 mmol), potassium carbonate (138 mg, 1 mmol), and a catalytic amount of potassium iodide, and then the reaction mixture was stirred for 12 hours at 80° C. The reaction mixture was filtered, concentrated, and purified by silica gel column chromatography (petroleum ether:ethyl acetate=100:1 to 1:1) to obtain compound 3-2 (103 mg) as a white solid with a yield of 70%.
LCMS [M+1]+=435.0, 437.0.
Compound 1-4 (60 mg, 0.17 mmol), compound 3-2 (73.9 mg, 0.17 mmol), sodium bicarbonate (42 mg, 0.5 mmol), and Pd(dppf)Cl2 (8 mg, 0.01 mmol) were added into a 10 mL microwave tube. The system was added with dioxane (4 mL) and H2O (1 mL). The microwave tube was sealed under nitrogen atmosphere, and the reaction mixture was reacted at 120° C. for 1 hour under microwave irradiation. After the reaction was complete, the reaction mixture was diluted with petroleum ether (9 mL) and ethyl acetate (2 mL). The reaction mixture was then dried over anhydrous sodium sulfate, and filtered by a small amount of silica gel layer to remove inorganic salts and palladium black. The filtrate was concentrated to obtain compound 3-3 (88 mg) as a light brown crude product, which was used directly in the next step without further purification.
LCMS [M+1]+=574.2.
Ethyl 4′-(4-acetoxybutoxy)-4″-(pyrrolidin-1-yl)-3″-(trimethylsilyl)-[1,1′:3′,1″-terphenyl]-4-carboxylate (compound 3-3, 88 mg of the crude product) was placed in a 25 mL single-necked flask. Compound 3-3 was dissolved in tetrahydrofuran (3 mL). NaOH aqueous solution (1 M, 1 mL) was added to the reaction system. The reaction system was stirred for 2 hours at 40° C. After the reaction was complete, the reaction system was slowly adjusted to neutrality with formic acid. The reaction mixture was directly purified by reversed-phase column chromatography (H2O/MeCN, 30% to 100%, 0.05% FA), and the resulting eluate was concentrated until a large amount of solid precipitated, filtered, washed with acetonitrile (1 mL×2), and dried to obtain compound I-3 (26 mg) as a white solid product.
LCMS [M+1]+=504.2.
1H NMR (800 MHz, DMSO-d6)=8.04-7.95 (m, J=8.4 Hz, 2 H), 7.83-7.78 (m, J=8.5 Hz, 2 H), 7.67 (dd, J=2.4, 8.5 Hz, 1 H), 7.61 (d, J=2.4 Hz, 1 H), 7.63 (d, J=2.2 Hz, 1 H), 7.54 (dd, J=2.2, 8.3 Hz, 1 H), 7.31 (d, J=8.4 Hz, 1 H), 7.21 (d, J=8.7 Hz, 1 H), 4.06 (t, J=6.5 Hz, 2 H), 3.42 (t, J=6.4 Hz, 2 H), 3.00 (br. s., 4 H), 1.89 (t, J=2.9 Hz, 4 H), 1.76-1.72 (m, 2 H), 1.56-1.51 (m, 2 H), 0.28-0.26 (s, 9 H).
4-Bromo-2-iodoaniline (compound 4-1, 0.9 g, 3 mmol) was dissolved in acetonitrile (20 mL) in a 50 mL sealed tube, and iodoethane (3.1 g, 20 mmol) and potassium carbonate (810 mg, 6 mmol) were sequentially added thereto at room temperature, and after the addition was complete, the flask was sealed tightly, and the mixture was stirred for 12 hours at 80° C. The solid insoluble material was filtered, then the filtrate was evaporated to dryness by rotary evaporation, and the residue was purified by silica gel column chromatography (mobile phase: petroleum ether:ethyl acetate=100 to 20:1) to obtain compound 4-2 (350 mg, 1.0 mmol) as a yellow oil with a yield of 33%.
LCMS [M+1]+=353.9, 355.9.
4-Bromo-N,N-diethyl-2-iodoaniline (compound 4-2, 350 mg, 1.0 mmol) was added into a 50 mL three-necked flask, dissolved in tetrahydrofuran (10 mL), and the mixture was stirred for 5 minutes in a dry ice acetone bath (−78° C.). n-Butyllithium (0.5 mL, 2.5 M) was added slowly dropwise to the solution under nitrogen atmosphere, and after the dropwise addition was complete, the reaction mixture was continuously stirred and reacted for 1 hour at −78° C. Then, chlorotrimethylsilane (180 mg, 1.7 mmol) was added slowly dropwise to the reaction mixture, and the temperature was kept constant at −78° C. After the dropwise addition was complete, the reaction mixture was slowly warmed to room temperature while stirring and stirred overnight. The reaction was quenched by saturated ammonium chloride aqueous solution (10 mL), and the reaction mixture was extracted with ether (3×20 mL). The organic phases were combined, washed with saturated brine (1×10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated to dryness by rotary evaporation to obtain a light yellow residue. The residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether=1:20) to obtain compound 4-3 (150 mg, 0.5 mmol) as a light yellow oil with a yield of 50%.
LCMS [M+1]+=300.0, 302.0.
4-Bromo-N,N-diethyl-2-(trimethylsilyl)aniline (compound 4-3, 150 mg, 0.5 mmol), bis(pinacolato)diboron (153 mg, 0.6 mmol), potassium acetate (98 mg, 1.0 mmol), and Pd(dppf)Cl2 (8 mg, 0.01 mmol) were added into a 10 mL microwave tube. And dioxane (4 mL) was added into the tube. The microwave tube was sealed under nitrogen atmosphere, then heated, and reacted at 120° C. for 1 hour. After the reaction was complete, the reaction mixture was diluted with petroleum ether (9 mL), separated by flash column chromatography with a small amount of silica gel layer, and filtered to remove inorganic salts and palladium black. The filtrate was concentrated to obtain compound 4-4 (180 mg) as a light brown crude product. The crude product was used directly in the next reaction step without purification.
LCMS [M+1]+=348.2.
Compound 4-4 (60 mg, 0.17 mmol), compound 1-7 (68 mg, 0.17 mmol), sodium bicarbonate (42 mg, 0.5 mmol), and Pd(dppf)Cl2 (8 mg, 0.01 mmol) were added into a 10 mL microwave tube. The system was added with dioxane (4 mL) and H2O (1 mL). The microwave tube was sealed under nitrogen atmosphere, and the reaction mixture was reacted at 120° C. for 1 hour under microwave irradiation. After the reaction was complete, the reaction mixture was diluted with petroleum ether (9 mL) and ethyl acetate (2 mL). The reaction mixture was then dried over anhydrous sodium sulfate, and filtered by a small amount of silica gel layer to remove inorganic salts and palladium black. The filtrate was concentrated to obtain compound 4-5 (80 mg) as a light brown crude product, which was used directly in the next step without further purification.
LCMS [M+1]+=548.2.
Ethyl 4′-(2-acetoxyethoxy)-4′-(diethylamino)-3′-(trimethylsilyl)-[1,1′:3′,1″-terphenyl]-4-carboxylate (compound 4-5, 80 mg of the crude product) was placed in a 25 mL single-necked flask. Compound 4-5 was dissolved in tetrahydrofuran (3 mL). NaOH aqueous solution (1 M, 1 mL) was added to the reaction system. The reaction system was stirred for 2 hours at 40° C. After the reaction was complete, the reaction system was slowly adjusted to neutrality with formic acid. The reaction mixture was directly purified by reversed-phase column chromatography (H2O/MeCN, 30% to 100%, 0.05% FA), and the resulting eluate was concentrated until a large amount of solid precipitated, filtered, washed with acetonitrile (1 mL×2), and dried to obtain compound I-4 (17 mg) as a white solid product.
LCMS [M+1]+=478.2.
1H NMR (DMSO-d6, 800 MHz) δ 7.93-7.90 (m, 2H), 7.80-7.77 (m, 2H), 7.65-7.63 (m, 2H), 7.60-7.58 (m, 2H), 7.26 (d, J=8.2 Hz, 1H), 7.20 (d, J=8.5 Hz, 1H), 4.08 (t, J=5.2 Hz, 2H), 3.70-3.67 (m, 2H), 3.05-2.94 (m, 4H), 1.12-1.04 (m, 6H), 0.27-0.25 (m, 9H).
1,2-Bis(chlorodimethylsilyl)ethane (compound 5-1, 3.00 g, 13.94 mmol) was taken and dissolved in a 30 mL solution of anhydrous tetrahydrofuran, and the system was charged with argon. Ethynylmagnesium chloride (70 mL, 0.5 mol/L, 35.00 mmol) was added slowly dropwise thereto at room temperature. The reaction mixture was stirred at room temperature for 1 hour and then refluxed for 1 hour. After the reaction was complete, the reaction mixture was added with saturated ammonium chloride solution to quench. The reaction system was added with an appropriate amount of ethyl acetate and washed twice with saturated brine, and the organic phases were collected and dried over anhydrous sodium sulfate. The organic phase was filtered, evaporated to dryness under reduced pressure, and the crude product was purified by silica gel column chromatography (petroleum ether) to obtain compound 5-2 (1.80 g, 9.26 mmol) as a colorless liquid with a yield of 66%.
1H NMR (300 MHz, CDCl3) δ 2.37 (s, 2H), 0.61 (s, 4H), 0.18 (s, 12H).
Iodine (20.00 mg, 0.08 mmol) was dissolved in 10 mL of anhydrous acetonitrile, then zinc (45.00 mg, 0.69 mmol) was added thereto, and the mixture was stirred at room temperature until the yellow color disappeared and a gray suspension appeared. The system was charged with argon, and compound 5-2 (1.38 g, 7.10 mmol), 2-ethynyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (1.40 mg, 9.21 mmol), and a 0.1 M solution of cobalt(II) iodide (2.00 mL, 0.20 mmol) were sequentially added thereto at room temperature. The system was switched to react at 50° C., monitored by TLC, and the reaction was terminated when compound 5-2 was completely consumed. The system was initially purified by silica gel column chromatography (ether:n-hexane=4:1), then the organic phases were combined, and the solvent was evaporated to dryness under reduced pressure to obtain a crude product as a yellow liquid. The crude product was purified again by silica gel column chromatography (n-hexane) to obtain compound 5-3 (0.50 g) as a colorless crystal with a yield of 20.3%.
1H NMR (300 MHz, CDCl3) δ 7.84 (s, 1 H), 7.68 (br s, 1 H), 7.41 (br s, 1 H), 1.22 (s, 12 H), 0.90 (s, 4 H), 0.16 (s, 6 H), 0.12 (s, 6 H).
Compound 1-7 (61 mg, 0.15 mmol), compound 5-3 (52 mg, 0.15 mmol), sodium bicarbonate (42 mg, 0.5 mmol), and Pd(dppf)Cl2 (8 mg, 0.01 mmol) were added into a 10 mL microwave tube. The system was added with dioxane (4 mL) and H2O (1 mL). The microwave tube was sealed under nitrogen atmosphere, and the reaction mixture was reacted at 120° C. for 1 hour under microwave irradiation. After the reaction was complete, the reaction mixture was diluted with petroleum ether (2 mL) and ethyl acetate (9 mL). The reaction mixture was dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (petroleum ether/ethyl acetate=100 to 10/1) to obtain compound 5-4 (70 mg) as a colorless oil with a yield of 85.3%.
LCMS [M+1]+=547.2.
1H NMR (800 MHz, DMSO-d6) δ 7.78 (d, J=8.4, 2 H), 7.63 (d, J=8.4, 2 H), 7.52 (d, J=1.2 Hz, 1 H), 7.50 (dd, J=2.5, 8.5 Hz, 1 H), 7.43 (d, J=2.4 Hz, 1 H), 7.37-7.31 (m, 2 H), 7.05 (d, J=8.6 Hz, 1 H), 4.11 (q, J=7.1 Hz, 2 H), 4.09-4.05 (m, 4 H), 1.76 (s, 3 H), 1.11 (t, J=7.1 Hz, 3 H), 0.78 (s, 4 H), 0.02-0.02 (m, 12 H).
Ethyl 4′-(2-acetoxyethoxy)-3′-(1,1,4,4-tetramethyl-1,2,3,4-tetrahydrobenzo[b][1,4]disilan-6-yl)-[1,1′-biphenyl]-4-carboxylate (compound 5-4, 70 mg, 0.128 mmol) was placed in a 25 mL single-necked flask. Compound 5-4 was dissolved in tetrahydrofuran (3 mL). NaOH aqueous solution (1 M, 1 mL) was added to the reaction system. The reaction system was stirred for 2 hours at 40° C. After the reaction was complete, the reaction system was slowly adjusted to neutrality with formic acid. The reaction mixture was extracted with ethyl acetate (20 mL), dried over anhydrous sodium sulfate, concentrated to about 1 mL of solvent, and then added with 10 mL of acetonitrile. When a large amount of solid precipitated, the mixture was filtered and dried to obtain I-5 (21 mg) as a white solid with a yield of 34.4%.
LCMS [M+1]+=477.2.
1H NMR (800 MHz, DMSO-d6) δ 7.74 (d, J=8.4 Hz, 2 H), 7.59-7.53 (m, 3 H), 7.45 (dd, J=2.4, 8.6 Hz, 1 H), 7.42-7.36 (m, 1 H), 7.36-7.30 (m, 2 H), 7.00 (d, J=8.6 Hz, 1 H), 3.87 (t, J=5.1 Hz, 2 H), 3.48 (t, J=5.1 Hz, 2 H), 0.76 (s, 4 H), 0.03-0.02 (m, 12 H).
Compound 2-2 (63 mg, 0.15 mmol), compound 5-3 (52 mg, 0.15 mmol), sodium bicarbonate (42 mg, 0.5 mmol), and Pd(dppf)Cl2 (8 mg, 0.01 mmol) were added into a 10 mL microwave tube. The system was added with dioxane (4 mL) and H2O (1 mL). The microwave tube was sealed under nitrogen atmosphere, and the reaction mixture was reacted at 120° C. for 1 hour under microwave irradiation. After the reaction was complete, the reaction mixture was diluted with petroleum ether (2 mL) and ethyl acetate (9 mL). The reaction mixture was dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (petroleum ether/ethyl acetate=100 to 10/1) to obtain compound 6-2 (75 mg) as a colorless oil with a yield of 89.2%.
LCMS [M+1]+=561.2.
1H NMR (800 MHz, DMSO-d6) δ 7.79-7.78 (m, 2 H), 7.64-7.62 (m, 2 H), 7.51-7.49 (m, 2 H), 7.41 (d, J=2.5 Hz, 1 H), 7.35 (d, J=7.6 Hz, 1 H), 7.30 (dd, J=1.8, 7.6 Hz, 1 H), 7.03 (d, J=8.7 Hz, 1 H), 4.11 (q, J=7.2 Hz, 2 H), 3.91 (t, J=6.2 Hz, 2 H), 3.88 (t, J=6.4 Hz, 2 H), 1.80-1.78 (m, 2 H), 1.73 (s, 3 H), 1.12 (t, J=7.1 Hz, 3 H), 0.78 (s, 4 H), 0.02 (s, 6 H), 0.00 (s, 6 H).
Ethyl 4′-(3-acetoxypropoxy)-3′-(1,1,4,4-tetramethyl-1,2,3,4-tetrahydrobenzo[b][1,4]disilan-6-yl)-[1,1′-biphenyl]-4-carboxylate (compound 6-2, 75 mg, 0.133 mmol) was placed in a 25 mL single-necked flask. Compound 6-2 was dissolved in tetrahydrofuran (3 mL). NaOH aqueous solution (1 M, 1 mL) was added to the reaction system. The reaction system was stirred for 2 hours at 40° C. After the reaction was complete, the reaction system was slowly adjusted to neutrality with formic acid. The reaction mixture was extracted with ethyl acetate (20 mL), dried over anhydrous sodium sulfate, concentrated to about 1 mL of solvent, and then added with 10 mL of acetonitrile. When a large amount of solid precipitated, the mixture was filtered and dried to obtain I-6 (40 mg) as a white solid with a yield of 61.2%.
LCMS [M+1]+=491.2.
1H NMR (800 MHz, DMSO-d6) δ 7.78-7.74 (m, 2 H), 7.61-7.58 (m, 2 H), 7.51 (d, J=1.3 Hz, 1 H), 7.50-7.47 (m, 1 H), 7.39 (d, J=2.5 Hz, 1 H), 7.37-7.33 (m, 1 H), 7.31 (d, J=1.8 Hz, 1 H), 7.01 (d, J=8.7 Hz, 1 H), 3.90 (t, J=6.3 Hz, 2 H), 3.30 (t, J=6.2 Hz, 2 H), 1.62 (t, J=6.3 Hz, 2 H), 0.77 (s, 4 H), 0.02-0.02 (m, 12 H).
The HEK-293 cell line (ATCC #CRL-1573) was used to test the agonist activity of the compound on RARγ and RARα.
The experimental materials are shown in Table 1:
The experimental results of some compounds of the present disclosure are shown in Table 2.
It can be seen from the data in Table 2 that the agonist activity of compounds I-1, I-2, and I-5 on RARγ is equal to or stronger than that of Trifarotene, and the selectivity of compounds I-1, I-2, I-3, and I-5 on RARγ is better than that of Trifarotene.
The metabolic stability of the compounds was tested using human hepatocytes.
The results show that compound I-1 is metabolized faster in human hepatocytes, with less than 1% of the prototype compound remaining after 240 minutes of incubation in hepatocytes, while Trifarotene still has 13.57% of the prototype compound after 240 minutes of incubation, indicating that compound I-1 has a lower systemic exposure when it enters the blood circulatory system and is expected to have a better safety profile.
| Number | Date | Country | Kind |
|---|---|---|---|
| 202110459864.X | Apr 2021 | CN | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2022/089139 | 4/26/2022 | WO |
